B-cell targeting in rheumatoid arthritis and other autoimmune diseases

@article{Edwards2006BcellTI,
  title={B-cell targeting in rheumatoid arthritis and other autoimmune diseases},
  author={J. Edwards and G. Cambridge},
  journal={Nature Reviews Immunology},
  year={2006},
  volume={6},
  pages={394-403}
}
B-cell-targeted therapy for autoimmune disease emerged from theoretical proposition to practical reality between 1997 and 1998, with the availability of the B-cell-depleting monoclonal antibody rituximab. Since then, a score of autoantibody-associated disorders have been treated, with most convincing evidence of efficacy seen in subjects with rheumatoid arthritis. Several classes of B-cell-targeted agent are now under investigation. From the outset, a major goal of B-cell targeting has been the… Expand
B-Cell Depletion and Repopulation in Autoimmune Diseases
B-cell: a logical target for treatment of rheumatoid arthritis.
B cell depletion in systemic lupus erythematosus.
The potential utility of B cell-directed biologic therapy in autoimmune diseases
[B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
  • Yoshiya Tanaka
  • Medicine
  • Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • 2009
B-Cell-Targeted Therapy for Systemic Lupus Erythematosus
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 120 REFERENCES
New treatments for SLE: cell-depleting and anti-cytokine therapies.
Improvement of refractory rheumatoid arthritis after depletion of B cells
Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations
...
1
2
3
4
5
...